Thank you, Gavin. Good morning everyone. Let me start our financial overview with our sales development in Q3 2024. We grew sales by 25%, excluding the FX headwind. This means further acceleration from our Q2 growth and brings the year-to-date average to about 20% from a slow start of the year. We are looking at the contribution of the business units. We are very happy to see that both growth and core markets are significantly contributing to the group's growth, and also that the improvements in the Emerging division's sales make it a real contributor to our year-over-year sales performance in both segments. The key driver for the growth was the nicotine pouch category, which, excluding FX, accounted for 20% of the overall 25% growth. The measures we implemented to manage the decline in snus largely resulted in this category remaining largely flat versus last year. Moving to slide seven and our profitability. Profitability also remained robust. This is consistent with the previous quarters of 2024. Our adjusted EBIT grew by 81% to 33.1 million, which means a 3.5% adjusted EBIT margin, an improvement from 2.4% last year. The result was supported by the sustained margin expansion, which we partly reinvested into the team, mainly to support our Emerging division, Core segment, and Growth segment. Profitability before investments into the emerging segment reached 4.3% on an adjusted EBIT level. Important to highlight that in the quarter, we created a reserve for the San Francisco complaint, based on the available facts, supported by external legal advice. Moving to the next slide. To our core markets. Here in core markets, we achieved a 16% growth, excluding the FX headwind of 3% in Norway, driven by the nicotine pouch category which performed well in both markets. The nicotine pouch volume grew 32%, demonstrating consistent performance both in Sweden and Norway in terms of profitability. Our adjusted EBITDA is up by 0.7 percentage points versus the same period last year, driven by the improved media and insights revenues which demonstrate the robustness of our business model. Moving to slide nine, and in our growth markets, our sales grew by 44%, excluding the 4% currency headwind. We are happy with the nicotine pouch development across the board in both markets. Adjusted EBITDA was 2.5 million. 0.9% of our sales are in line with previous quarters. Active customer growth was exceptional. The increased search volume demonstrates the opportunity we see for further online channel penetration and growth across the market. Slide ten and our emerging markets. In the big scheme of things, these markets are still small. However, the sequential quarter-over-quarter growth remained robust compared to Q2 2024, where sales were up by 64%. Active customers now reached 20,000 within the quarter. The investment for this business segment remained consistent, and the EBITDA for this business unit was -7.8 million in Q3. This represents a 0.8% reinvestment on a total level. Moving to slide 11 and our selected KPIs here, I would like to highlight two numbers. Firstly, the investment level, because year to date Q3 we invested 69 million SEK, which is 2.5% slightly above the historical averages. But as we highlighted several times earlier, this is not a flat line. Right now. We are working hard on the overhaul of our backend and frontend infrastructure, which is not visible in these numbers. However, as soon as these projects are completed in the coming quarters, this number will go down to the previously stated levels. Our net debt to adjusted EBITDA ratio is 0.8. Looking at the last 12 months, which shows and represents a very robust and healthy balance sheet that we maintain for the group. With this, I hand the word back to Gavin to guide us through the legal and regulatory developments.